Jun. 18 at 9:08 PM
$GCTK CBGM represents a new modality in glucose monitoring, and ongoing engagement with the FDA remains an important part of advancing the program. As previously communicated, we continue working toward regulatory alignment while progressing preparations for the planned clinical study and look forward to providing a further update on our progress in Q3. We want to keep shareholders informed as key development and regulatory milestones are reached, and we intend to continue sharing updates as progress is made.
